Literature DB >> 16326406

Combined treatment of hepatoblastoma with transcatheter arterial chemoembolization and surgery.

Jiang Xuewu1, Li Jianhong, Hu Xianliang, Chen Zhongxian.   

Abstract

Hepatoblastoma (HB) frequently presents at an advanced and unresectable stage. Transcatheter arterial chemoembolization (TACE) had been attempted to improve the feasibility of removing the bulky tumor in the authors' hospital and the results were presented here to evaluate the effectiveness and therapeutic role of TACE in the HB infants. Eight patients (6 boys, 2 girls), ranging in age from 2 months to 12 months, had unresectable HB based on clinical manifestation, B-ultrasound (B-US), chest X-ray film, computed tomography (CT), blood chemistry, and serum alpha-fetoprotein (AFP), and were subjected to TACE 1-3 times. On each TACE, Adriamycin (ADR, 20 mg/m2), vincristine (VCR, 1.5 mg/m2), and cisplatin (CDDP, 40 mg/m2) dispersed in 5-10 mL lipiodol were infused into the tumor, and stainless-steel embolization coils were released into the main feeding artery until completely embolized. Then, all the patients were reexamined once a month. Digital subtractive angiography was performed and the therapeutic strategy of further TACE or surgery was individualized in terms of the changes of tumor stain and the newly forming feeding artery. Six children (75%) had a marked response after the first TACE and were judged as being surgically resectable, but one boy died of pneumonia just before the scheduled operation and another boy preferred further TACE. The other 2 patients had only a partial response and required further TACE before the operation. Thus 6 children eventually underwent complete surgical resection and 1 boy achieved successful disappearance of tumor after 3 episodes of TACE alone. Seven children had an excellent recovery and remained tumor-free for 15-49 months. The results indicate that TACE is an effective and useful preoperative therapeutic choice for unresectable hepatoblastoma, and can improve the resectablity of the bulky tumor and the survival rate of HB patients. Multiple TACE could enhance the therapeutic effect and should be considered if indicated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16326406     DOI: 10.1080/08880010500313256

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT).

Authors:  Eiso Hiyama; Yuka Ueda; Yoshiyuki Onitake; Shou Kurihara; Kenichiro Watanabe; Tomoro Hishiki; Tatsuro Tajiri; Komei Ida; Michihiro Yano; Satoshi Kondo; Takaharu Oue
Journal:  Pediatr Surg Int       Date:  2013-10       Impact factor: 1.827

2.  Ruptured hepatoblastoma successfully treated with cisplatin monochemotherapy: A case report.

Authors:  Tianyou Yang; Tianbao Tan; Jiliang Yang; Jing Pan; Chao Hu; Jiahao Li; Tao Xu; Yan Zou
Journal:  Mol Clin Oncol       Date:  2018-06-04

3.  Cure of Hepatoblastoma Through Transcatheter Arterial Chemoembolization.

Authors:  Tianyou Yang; Jiliang Yang; Tianbao Tan; Jing Pan; Chao Hu; Jiahao Li; Yan Zou
Journal:  Glob Pediatr Health       Date:  2017-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.